Life Science Nation Newsletter | January 17, 2019 | Issue 300

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI Vienna Registration is Open!
Save €300 when you register by February 8th
   Life Science Investor Mandates
(Jan. 10 - Jan. 16 )
with Over $1B AUM Invests in Therapeutics, Devices, and Diagnostics Technologies with Strong China Angle
Invests in Global ife Science & Healthcare Related Opportunities with Taiwan Market Potential
Actively Seeking All Early-Stage Technologies that Focus on Advancing Therapies for CNS Diseases
Invests Up to $15M in Software-Driven Devices and Diagnostics & Digital Health Companies in the USA
LSN Services
LSN Videos
LSN Media Partners
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) and the Stetson Family Office (SFO) relationship began over 18 months ago when Chuck Stetson decided that the Redefining Early Stage Investments (RESI) Conference Series was the perfect vehicle for his global family office network to achieve two of his goals. The first goal is matching the "dollars and desires" of the early stage family office investor with the vetting capability of LSN's vast early stage angel network. The second goal was using RESI to surface the companies that needed the capital to make it through early stage development.

Chuck's vision morphed into an official entity called the Global Family Office BioForum (GFOB), which he launched this year at RESI SF during the JP Morgan event in San Francisco. GFOB is an alliance of international family offices. This organization currently spans 18 cities in the U.S., Europe and Asia, and now has recently expanded to working in cooperation with the Angel Capital Association with 13,000 members in 260 organizations. Click to read the full press release here

By Claire Jeong, Senior Research Analyst, LSN

Last week's RESI San Francisco during JP Morgan brought almost 1,200 attendees, making it our largest conference to date. This included over 500 investors and 500 early-stage companies in our usual sectors of focus - therapeutics, medical devices, diagnostics, and digital health. Here is the breakdown of technology sectors and investor types that were represented:

The partnering forum hit full capacity earlier than anticipated, so we had to close registration early to provide the best accommodation possible for all attendees. We did our best to provide as many additional meeting areas as possible...

By Jessica Yang, Senior Investor Research Analyst & Asia BD, LSN

Back in October 2018, LSN cooperated with BIOMED Taiwan and the Biomedical Commercialization Center to hold a three-day Biotech/Medtech Startups Fundraising & Entrepreneurship Training Bootcamp in Taiwan. This event was held to help bring Taiwan's biomedical startups to the international stage and to give the companies a chance to learn how to seek fundraising opportunities. Dennis Ford, LSN Founder and CEO, Greg Mannix, VP of International Business Development, and Jessica Yang, Senior Investor Research Analyst & Asia BD were invited to visit Taiwan to teach the Bootcamp as well as provide one-on-one startup fundraising consultations. This was the first time that Taiwan's biomedical industry has cooperated in holding a fundraising training program with an international early-stage startup fundraising consulting firm, such as LSN.

On Oct 16, 2018, the first day of the training program, Dennis gave a top-to-bottom master class on outbound global fundraising campaigning to over 90 Taiwanese biomedical startups...

Created & Produced by